{"id":"W4298139160","doi":"10.1200/jco.2022.40.28_suppl.126","title":"Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1 > 50%: Comparison between clinical trials and the real world.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Internal medicine; Stage (stratigraphy); Progression-free survival; Cancer; Oncology; Retrospective cohort study; Univariate analysis; Chemotherapy; Multivariate analysis; Surgery; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004088671,0.0002240781,0.000925859,0.000353643,0.0001636479,0.0007508279,0.000339944,0.0007267946,0.001027703],"category_scores_gemma":[0.005483616,0.0001714572,0.001026722,0.00042614,0.0003739375,0.0007292712,0.0002477759,0.0005560348,0.0001551913],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001032395,"about_ca_system_score_gemma":0.0004663451,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000343896,"about_ca_topic_score_gemma":0.0006634637,"domain_scores_codex":[0.9977373,0.001277066,0.0002805726,0.0003425761,0.0002543686,0.0001081021],"domain_scores_gemma":[0.995561,0.001809869,0.001944932,0.0001749041,0.0002386175,0.0002706507],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3886583,0.003884023,0.4761234,0.002395831,0.004886008,0.0002658324,0.0003958987,0.0009257947,0.005378798,0.0002939575,0.001150611,0.1156417],"study_design_scores_gemma":[0.04351076,0.234644,0.7001483,0.0004263381,0.005532346,0.001238831,0.000359954,0.00250718,0.003426129,0.0002711871,0.007870427,0.00006452823],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899024,0.008888409,0.0001020148,0.000141805,0.00004102868,0.0001049613,0.000190115,0.000005038379,0.0006241464],"genre_scores_gemma":[0.9985598,0.0008919744,0.00007741552,0.00007148658,0.00004411214,0.00005788265,0.000211074,0.000001429146,0.00008470471],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004088671,"threshold_uncertainty_score":0.02162319,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1215283272009055,"score_gpt":0.4612122972666582,"score_spread":0.3396839700657528,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}